GFAP and Alzheimer disease: Because reactive astrocytes are conventionally identified by their GFAP immunoreactivity and GFAP expression in non-reactive (resting) astrocytes is often below the detection level of immunohistochemistry, it is not uncommon to misinterpret the enhanced GFAP immunoreactivity seen in the AD brain as evidence of astrocyte proliferation.